Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

19

Revenue 2017

Keytruda

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Keytruda was produced by Merck & Co..

Keytruda begins pursuit of rivals in small cell lung cancer

Keytruda begins pursuit of rivals in small cell lung cancer Set for competition with Opdivo. Merck &Co. has gained approval for Keytruda for use in third line treatment of small cell lung cancer (SCLC). ... Merck is already exploring Keytruda’s use in combination with chemotherapy in a phase 3 KEYNOTE-604 study.

Merck bulks up in cancer with $2.2bn Peloton buy

Merck bulks up in cancer with $2.2bn Peloton buy It ties in with CEO Ken Frazier’s pledge to make bolt-on acquisitions to bolster Merck’s internal R&D as it starts to look beyond immuno-oncology powerhouse Keytruda ... Keytruda is already making waves in RCC, having been approved for first-line RCC

Keytruda monotherapy fails in triple negative breast cancer

Keytruda monotherapy fails in triple negative breast cancer One such study is Keynote-355, which looks at Keytruda combined with chemotherapy (nab-paclitaxel, paclitaxel, gemcitabine, carboplatin) vs. ... Keytruda is far ahead of all its rivals in terms of revenues, and is set to exceed 8bn in global sales this

Research charity LifeArc cashes $1.2bn royalty from Keytruda

Research charity LifeArc cashes $1.2bn royalty from Keytruda Marketed by MSD (Merck &Co in North America), Keytruda (pembrolizumab) is set to reach sales of $8bn this year, and is the leader in the immunotherapy class redefining cancer treatment – and ... CPPIB Credit Europe, a subsidiary of Canada Pension

Iovance up on good ASCO abstract data for cervical cancer therapy

Iovance up on good ASCO abstract data for cervical cancer therapy That compares very well with results seen with Merck &Co’s PD-1 inhibitor Keytruda (pembrolizumab) in recurrent cervical cancer, where studies indicated an ORR of around 14%, while for chemotherapy ... That study shows that the TIL can be given after

[ Previous 5 results ] 6 7 8 9 10 11 12 13 14 15 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Pharma index map
The 2019 CPhI Pharma Index Report
Examining this year’s industry performance...
Five key trends in precision and personalised healthcare
Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications
Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...

Infographics